Oncoethix GmbH clinical trials
Acquired by Merck & Co., Inc, Dec 2014 · source ↗
The registry lists 5 studies whose lead sponsor is Oncoethix GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 26, 2021.
- 5studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Oncoethix GmbH became part of Merck & Co., Inc
- 5
- First submitted after Oncoethix GmbH became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Oncoethix GmbH’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 212
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)5 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Merck & Co., Inc studies →
- A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)CompletedNCT01713582Phase 1
Sponsor listed in the registry: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoethix GmbH became part of Merck & Co., Inc
- A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)TerminatedNCT02296476Phase 2
Sponsor listed in the registry: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoethix GmbH became part of Merck & Co., Inc
- A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)CompletedNCT02259114Phase 1
Sponsor listed in the registry: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoethix GmbH became part of Merck & Co., Inc
- A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)WithdrawnNCT02303782Phase 1/2
Sponsor listed in the registry: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoethix GmbH became part of Merck & Co., Inc
- A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid TumorsStatus unknownNCT01724320Phase 1
Sponsor listed in the registry: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoethix GmbH became part of Merck & Co., Inc